NRIX
NASDAQ HealthcareNurix Therapeutics, Inc. - Common stock
Biotechnology
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
�� 市场数据
| 价格 | $17.51 |
|---|---|
| 成交量 | 855,933 |
| 市值 | 1.81B |
| 贝塔系数 | 1.980 |
| RSI（14日） | 74.2 超买 |
| 200日均线 | $13.89 |
| 50日均线 | $15.72 |
| 52周最高 | $22.50 |
| 52周最低 | $8.20 |
| Forward P/E | -6.15 |
| Price / Book | 3.76 |
🎯 投资策略评分
NRIX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🚀 Moon Shot (91/100) — 此策略 高增长潜力（高贝塔 + 超卖）.
评分最低的策略： 💰 Dividend Daddy (6/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 NRIX in your text
粘贴任何文章、记录或帖子 — 工具将提取 NRIX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.